Recruiting

Observational Study

Sponsor:

Gemstone Biotherapeutics

Code:

NCT04090970

Conditions

Mohs Surgery

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Briagen

Study Details

Brief summary:

This research study is evaluating a study product called Briagen™ as a possible treatment for wound healing after Mohs procedure.

Conditions

Mohs Surgery

Study ID

NCT04090970

Start date

Aug 26, 2019

Status verified date

Dec, 2019

Completion date

May, 2020

Anticipated

Primary completion date

Mar, 2020

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Patient seeking treatment for wound created by Mohs or other full thickness skin excisions
2. Over 18 years of age
3. English-speaking
4. Presents for treatment within 24 hours of initial Mohs skin excision procedure.

Exclusion Criteria:

1. History of significant wound complications and non-compliance on wound maintenance instructions (infections, disturbing the wound during the healing process, etc.)
2. Known diagnosis of Diabetes
3. Active infection in the wound bed
4. Under 18 years of age

Study Design

Enrollment

30 participants

Anticipated

Interventions and Outcome Measures

Interventions

Briagen

Natural complex carbohydrate wound dressing for skin wounds

Primary outcome measure

  • Healing Time [ Time Frame: 28 days ]

Central Contacts and Locations

Central contacts

Emily English, PhD

443-682-7740info@gemstonebio.com

Locations

Dr. David Abramson

Recruiting

Englewood, New Jersey, United States, 07631

Contacts

David Abramson, MD

201-568-2977

Dermatology, Laser & Vein Specialists of the Carolinas

Recruiting

Charlotte, North Carolina, United States, 28207

Principal Investigator:

Girish Munavalli, MD

More Information

Sponsor

Gemstone Biotherapeutics

Last update posted

Dec 17, 2019

Last verified

Dec, 2019

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Gemstone Biotherapeutics on 2019-12-17.